Everything below concerns 合成肽. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
稳定性研究通常考察温度、光照、湿度和 pH 对肽链的影响。冻干粉在低温避光条件下较为稳定，复溶后则需控制保存时间并避免反复冻融。肽类可能发生氧化、脱酰胺、水解和聚集，这些变化会改变色谱纯度。强制降解实验用于识别主要降解途径并验证分析方法的专属性。
质量控制项目一般包括外观、身份、纯度、含量、有关物质、水分和微生物限度。身份确认可通过肽图谱、氨基酸分析和质谱完成，纯度则用面积归一化法计算。研究级材料与药品级材料的要求不同，前者常缺少完整药典验证。不同批次间杂质谱是否影响活性，仍是一个需要具体数据回答的问题。
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
The economist Amartya Sen observes that, in recent decades, famine has always been a problem of food distribution, purchasing power or poverty, since there has always been enough food for everyone in the world. There are also sociopolitical causes of malnutrition. For example, the population of a community might be at increased risk for malnutrition if government is poor and the area lacks health-related services. On a smaller scale, certain households or individuals may be at an even higher risk due to differences in income levels, access to land, or levels of education. Community plays a crucial role in addressing the social causes of malnutrition. For example, communities with high social support and knowledge sharing about social protection programs can enable better public service demands. Better public service demands and social protection programs minimise the risk of malnutrition in these communities. It is argued that commodity speculators are increasing the cost of food. As the real-estate bubble in the United States was collapsing, it is said that trillions of dollars moved to invest in food and primary commodities, causing the 2007–2008 food price crisis. The use of biofuels as a replacement for traditional fuels raises the price of food. The United Nations special rapporteur on the right to food, Jean Ziegler proposes that agricultural waste, such as corn cobs and banana leaves, should be used as fuel instead of crops. In some developing countries, overnutrition (in the form of obesity) is beginning to appear in the same communities where malnutrition occurs.
The original Norse settlers adopted the Gallo-Romance language of the Frankish land they settled, with their Old Norman dialect becoming known as Norman, Normaund or Norman French, an important literary language which is still spoken today in parts of mainland Normandy (Cotentinais and Cauchois dialects) and the nearby Channel Islands (Jèrriais and Guernésiais). The Duchy of Normandy, which arose from the Treaty of Saint-Clair-sur-Epte, was a great fief of medieval France. The Norman dukes exercised autonomous control of their holdings in Normandy, while at the same time being vassals owing fealty to the King of France, and under Richard I of Normandy (byname Richard sans Peur, meaning "Richard the Fearless"), the duchy was forged into a cohesive and formidable principality in feudal tenure. Between 1066 and 1204, as a result of the Norman conquest of England, most of the kings of England were also dukes of Normandy. Gradually, an Anglo-Norman culture developed in the British Isles. In 1204, Philip II of France seized mainland Normandy by force of arms, having earlier declared the Duchy of Normandy to be forfeit to him. It remained a disputed territory until the Treaty of Paris of 1259, when the English sovereign ceded his claim to the Duchy, except for the Channel Islands. In the present day, the Channel Islands (the Bailiwick of Guernsey and the Bailiwick of Jersey) are considered to be officially the last remnants of the Duchy of Normandy, and are not part of the United Kingdom but are instead self-governing Crown Dependencies.
Hydrogen selenide is an extremely toxic, corrosive gas. Selenium also occurs in organic compounds, such as dimethyl selenide, selenomethionine, selenocysteine and methylselenocysteine, all of which have high bioavailability and are toxic in large doses. The Occupational Safety and Health Administration (OSHA) has set the legal limit (permissible exposure limit) for selenium in the workplace at 0.2 mg/m3 over an 8-hour workday. The National Institute for Occupational Safety and Health (NIOSH) has set a Recommended exposure limit (REL) of 0.2 mg/m3 over an 8-hour workday. At levels of 1 mg/m3, selenium is immediately dangerous to life and health.
Sources: en.wikipedia.org
== Litigation == In 2016, the Supreme Court imposed a fine of ₹4 crore (US$420,000) on Dharampal Satyapal Limited for breaching commitments and causing delays in resolving a 2009 tax dispute. The company contested a ₹244 crore (US$25 million) tax demand related to Central Excise Duty, briefly applied to the Settlement Commission without reaching an agreement, and later faced dismissal of its petition by the Delhi High Court. DSL subsequently sought relief from the Supreme Court in 2013, securing a stay order against the tax demand.
He argued that the two food products are made of the same ingredient and that genetically speaking, soybeans are from China, though the specific variety was never mentioned. Food journalist Andreas Maryoto supported this idea, saying that tempeh might have been accidentally produced as the by-product of the tofu industry in Java in the 17th century, as discarded soybeans caught the spores of a whitish fungus that was found to be edible. In 2025, Zaelani formalized this as the "Okara-Tempe Hypothesis", proposing that tempeh originated from okara (tofu residue) that was naturally fermented before being adapted to whole soybeans. However, tahu was (and is still) made of white soybeans (Glycine max, native to Japan and China), as opposed to the earliest version of tempe dhele that was made of native black soybeans (Glycine soja). Tahu (tofu) made its way to Kediri in the 13th century and was consumed by the Mongolians who arrived in Java. Later, it was popular only among the rich (the complex production process and imported white soybeans led to its high price). Around the 17th or 19th century, tahu became available to everyone. Tempeh later began to be made with white soybeans, leading to the decreased use of its native black variety. Black soybeans have been replaced by other commodity plants since. The original version of tempe dhele has been forgotten as tahu has become the common people's food, and dependence on imported white soybeans grows.
However, some in the Japanese archaeological community remain skeptical about the presence of cattle in Japan during the Yayoi period, and there is a persistent view that they were brought to Japan from the Korean peninsula by the toraijin, a group of people who came to Japan in the mid-5th century during the Kofun period. At the Nango-Ōhigashi site in Gose City, Nara Prefecture, excavations revealed cow bones believed to date back to the 5th century. At the Funamiya Kofun Tumulus (late 5th century) in Asago City, Hyōgo Prefecture, pieces of a cow-shaped haniwa (clay figurine), believed to be the oldest in Japan, have been excavated. In addition, a cow-shaped haniwa was excavated from the Hashida No. 1 Tumulus in Tawaramoto Town, Shiki-gun, Nara Prefecture in the first half of the 6th century, and was designated as an Important Cultural Property of Japan in 1958. On the other hand, recent genetic studies have shown that Wagyu and Korean cattle (Hanwoo and others) differ greatly in their genetic information. Livestock cattle are divided into two major lineages: northern lineage cattle (Bos taurus) and Indian lineage cattle (Bos indicus), and both Wagyu and Korean cattle belong to the northern lineage and do not contain Indian lineage such as Zebu cattle. However, in terms of mitochondrial DNA haplogroups, haplogroup T4 (East Asian type) is predominant in the Wagyu (Japanese Black) at about 65%, while haplogroup T3 (European type) is predominant in Korean cattle at 66–83%.
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.